Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Goodwill (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Goodwill for 8 consecutive years, with $59.0 million as the latest value for Q4 2025.

  • Quarterly Goodwill changed 0.07% to $59.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.0 million through Dec 2025, changed 0.07% year-over-year, with the annual reading at $59.0 million for FY2025, 0.07% changed from the prior year.
  • Goodwill for Q4 2025 was $59.0 million at Akebia Therapeutics, roughly flat from $59.0 million in the prior quarter.
  • The five-year high for Goodwill was $59.0 million in Q1 2022, with the low at $55.1 million in Q1 2021.
  • Average Goodwill over 5 years is $58.4 million, with a median of $59.0 million recorded in 2022.
  • The sharpest move saw Goodwill grew 7.25% in 2022, then decreased 0.07% in 2024.
  • Over 5 years, Goodwill stood at $59.0 million in 2021, then changed by 0.0% to $59.0 million in 2022, then increased by 0.07% to $59.0 million in 2023, then fell by 0.07% to $59.0 million in 2024, then increased by 0.07% to $59.0 million in 2025.
  • According to Business Quant data, Goodwill over the past three periods came in at $59.0 million, $59.0 million, and $59.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.